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Abstract The anti-neutrophil cytoplasmic antibody (ANCA)-
associated vasculitides (AAV) are a group of disorders character-
ized by necrotizing inflammation of the small to medium vessels
in association with autoantibodies against the cytoplasmic region
of the neutrophil. Included in this definition are granulomatosis
with polyangiitis (GPA, formerly known as Wegener’s granulo-
matosis), microscopic polyangiitis (MPA) and eosinophilic gran-
ulomatosis with polyangiitis (formerly known as Churg–Strauss
syndrome). AAVare chronic, often relapsing diseases that can be
organ or life threatening. Despite immunosuppression, the mor-
bidity and mortality remain high. Renal involvement contributes
significantly to the morbidity with high numbers of patients
progressing to end-stage kidney disease. Current therapies have
enabled improvements in renal function in the short term, but
evidence for long-term protection is lacking. In MPA, renal in-
volvement is common at presentation (90%) and often follows a
more severe course than that seen in paediatric GPA. Renal bi-
opsy remains the ‘gold standard’ in diagnosing ANCA-
associated glomerulonephritis. While GPA andMPA are consid-
ered separate entities, the two are managed identically. Current
treatment regimens are extrapolated from adult studies, although
it is encouraging to see recruitment of paediatric patients to recent
vasculitis trials. Traditionally more severe disease has been man-
aged with the ‘gold standard’ treatment of glucocorticoids and
cyclophosphamide, with remission rates achieved of between 70
and 100%. Other agents employed in remission induction in-
clude anti-tumor necrosis factor-alpha therapy and mycopheno-
late mofetil. Recently, however, increasing consideration is being
given to rituximab as a therapy for children in severe or relapsing
disease, particularly for those at risk for glucocorticoid or cyclo-
phosphamide toxicity. Removal of circulating ANCA through
plasma exchange is a short-term measure reserved for severe or
refractory disease. Maintenance therapy usually involves azathi-
oprine. The aim of this article is to provide a comprehensive
review of paediatric AAV, with a focus on renal manifestations,
and to highlight the recent advances made in therapeutic
management.
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Introduction
The anti-neutrophil cytoplasmic antibody (ANCA)-associated
vasculitides (AAV) are a group of disorders characterized by
necrotizing inflammation of the small to medium vessels in
association with autoantibodies against the cytoplasmic region
of the neutrophil, namely proteinase 3 (PR3) and
myeloperoxidase (MPO). Included in this definition are gran-
ulomatosis with polyangiitis (GPA, formerly known as
Wegener’s granulomatosis), microscopic polyangiitis (MPA)
and eosinophilic granulomatosis with polyangiitis (EGPA;
formerly known as Churg–Strauss syndrome). AAV is a
chronic, often relapsing disease that can be organ or life threat-
ening [1, 2]. While modern immunosuppressive regimens
have dramatically improved the prognosis for AAV, the asso-
ciated disease and therapy-related morbidity and mortality re-
main high [3]. Renal involvement contributes significantly to
the morbidity seen in paediatric AAV, with high numbers of
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patients progressing to end-stage kidney disease (ESKD).
Current therapies have enabled improvements in renal func-
tion in the short term, but evidence for long-term protection is
currently lacking. The disease burden associated with AAV is
particularly important in children as they acquire educational
achievements and strive to attain satisfactory growth, devel-
opment and fertility, with the additional burden that they are
likely to live with the disease and associated therapies for
longer than their adult counterparts. The aim of this article is
to provide a comprehensive review of paediatric AAV with a
focus on its renal manifestations, as well as to highlight the
recent advances made in therapeutic management.
Diagnosis and classification
In 2005, the vasculitis working group of the Paediatric
Rheumatology European Society (PRES), supported by the
European League Against Rheumatism (EULAR) proposed
new paediatric-specific classification criteria for GPA [4],
which were validated in 2008 [5]. Major differences between
EULAR/Paediatric Rheumatology INternational Trials
Organisation (PRINTO)/PRES paediatric and the 1990
American College of Rheumatology (ACR) criteria were the
addition of computed tomography imaging for pulmonary
complications and more specific features for respiratory in-
volvement [5]. The criteria were unable to differentiate MPA
and EGPA from GPA due to the rarity of these subtypes, and
as such no formal criteria for children are available. Current
recommendations from the European Medicines Agency
(EMA) to differentiate MPA from GPA are therefore based
on an algorithm by Watts et al. [6], which has been validated
in paediatric GPA and MPA cases [7].
In 2012, the nomenclature was updated: Wegener’s granu-
lomatosis was renamed granulomatosis with polyangiitis, and
Churg–Strauss syndrome became eosinophilic granulomato-
sis with polyangiitis [8]. Given the lack of validated criteria
for AAV, the ACR criteria and Chapel Hill Consensus
Conference definitions are used as such [9].
Epidemiology
Although increasingly recognized, AAV remain rare. Due to
changes in classification criteria, the true incidence is unclear.
Primary systemic vasculitis (PSV) in UK children has an in-
cidence of 10.6 cases per 100,000 population [10]. AAV are
very rare; the estimated incidence of GPA in Europe is less
than 1 per 2 million population per year [11], with a Canadian
study suggesting a higher incidence at 6.39 per million popu-
lation [12]. The incidence of MPA and EGPA in children is
unknown [3] (Table 1).
In adult-onset GPA, males are slightly more at risk than
females [13]. The converse is seen in childhood disease,
where GPA has a female predominance and tends to present
around adolescence [1, 20]. Childhood MPA also peaks in
early adolescence (12 years, range 7–17 years) [14, 15]. The
geographical distribution of GPA has been shown to increase
with increasing latitude, in both northern and southern hemi-
spheres [16]. Ethnicity has also been associated with an in-
creased risk: in a multi-ethnic population from France, GPA,
MPA and EGPA were twofold more prevalent in subjects of
European descent than in non-Europeans [17].
Aetiology and pathogenesis
While several hypotheses have been posed, the exact patho-
genesis of AAVremains unclear. Both PR3-ANCA andMPO-
ANCA are strongly associated with AAV although they may
correlate with separate phenotypes: PR3-ANCA is associated
with a granulomatous vasculitis whereas MPO-ANCA corre-
lates with a necrotizing small-vessel vasculitis. Granulomata
are not a feature of MPO-ANCA-associated vasculitis. There
is increasing evidence that ANCA may play a primary role in
the development of necrotizing small-vessel vasculitis [18].
In vitro studies have demonstrated that ANCA can stimulate
neutrophils to produce reactive oxygen species and lytic en-
zymes [21]. Before this can occur, pro-inflammatory cyto-
kines [tumour necrosis factor-alpha (TNF-α), interleukin
(IL) 1 and IL 18] must prime the neutrophils, leading to the
upregulation of neutrophil adhesion molecules (CD11b) and
translocation of PR3/MPO antigens to the neutrophil surface
membrane. Subsequent interaction between ANCA and the
relevant ANCA-antigen activates the neutrophil, causing in-
creased vessel wall adherence and transmigration. The ensu-
ing ANCA-mediated activation results in neutrophil degranu-
lation and release of reactive oxygen species, resulting in vas-
culitis [19]. In vivo experimental studies have since confirmed
a role for MPO-ANCA in the development of necrotizing
vasculitis [18].
Observations that infectious episodes may trigger relapses
of AAV have led to the hypothesis that microbial factors may
play a role in disease pathogenesis. This possibility is support-
ed by placebo-controlled adult studies that demonstrate a sig-
nificant reduction in relapses for patients treated with co-
trimoxazole [22, 23].
Following reports of familial associations, evidence for ge-
netic susceptibility is increasing. A genome-wide association
study performed in 1233UK patients with AAVand replicated
in 1454 Northern European patients has demonstrated genetic
associations with AAV and revealed that GPA and MPA are
two genetically distinct conditions [24]. The strongest genetic
associations were found to correlate with the antigenic speci-
ficity of ANCA rather than the clinical phenotype, with anti-
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PR3-ANCA correlating with HLA-DP and the α-antitrypsin
gene (SERPINA1, a serine proteinase inhibitor for which PR3
is one of the substrates) and proteinase 3 (PRTN3) and anti-
MPO-ANCA associated with HLA-DQ [24].
Clinical features
The clinical features of disease in children and adults with
GPA and MPA, respectively, in Table 2.
Granulomatosis with polyangiitis
The differences between paediatric GPA and MPA presenta-
tion and adult data are shown in Table 2 [27, 29]. In 2007 a
collaboration between U.S. and Canadian centres led to the
establishment of the ARChiVe (A Registry for Childhood
Vasculitis: e-entry) vasculitis registry. This multi-centre group
have since described the largest cohorts of paediatric GPA to
date [20, 32].
Characteristic features of both adult and childhood
GPA include necrotizing granulomata of the upper and
lower respiratory tract, necrotizing vasculitis and glo-
merulonephritis (GN). Childhood GPA differs from adult
GPA in several key features [5]. Childhood disease is
frequently heralded by the presence of constitutional
symptoms such as fever, anorexia and weight loss [1].
Multi-organ or generalized disease is common,
consisting predominantly of ear, nose and throat
(80%), pulmonary (80%) and renal (75.4%) involve-
ment, respectively. Less frequently involved are the
musculoskeletal (57%), gastrointestinal (42%), eyes
(37%), skin (35%) and nervous systems (25%) [20].
Upper airway involvement in children is consistently re-
ported at presentation, with an incidence of 70–100% [20,
32], commonly manifesting as recurrent epistaxis or sinusitis.
Oral ulceration is also reported although without evidence of
granulomata on biopsy [2]. Chronic inflammation can result in
nasal septum perforation, saddle-nose deformity, chronic si-
nusitis and conductive hearing loss [1]. Respiratory symptoms
described in the ACR-defined ARChiVe cohort and other
studies include dyspnoea (59%) and chronic cough (52%),
hoarseness (12%), stridor (29%) and haemoptysis (18%), [2,
20].
In those children whose radiographs show changes, find-
ings include diffuse pulmonary infiltrates, nodules, cavitating
lesions and granulomata without cavitation. Pulmonary nod-
ules and haemorrhage are reported with a similar incidence [1,
20]. Severe pulmonary haemorrhage requiring mechanical
ventilation can occur in 16–20% of patients at presentation.
In comparison with adult disease, subglottic stenosis is a high-
ly specific feature of paediatric GPA, reportedly affecting up
to 50% of paediatric patients [33], and can present indepen-
dently of systemic disease [34]. As such, it has been included
in new classification criteria [5].
Renal manifestations of childhood GPA contribute to
significant morbidity. Presentation can vary from urinary
sediment abnormalities or mild renal dysfunction to
acute kidney injury requiring renal replacement therapy
(RRT) [1, 20, 32]. A diagnosis of glomerulonephritis
based on biopsy findings is common. In a single-
centre review of biopsy-proven ANCA-associated glo-
merulonephritis, significant acute kidney injury [glomer-
ular filtration rate (GFR) <60 ml/min/1.73 m2) and/or
nephrotic-range proteinuria at presentation was found
in 57% (4 of 7) patients with childhood GPA [35].
Table 1 The incidence of anti-neutrophil cytoplasmic antibody-associated vasculitides in adult and childhood populations according to the literature
Reference Country of study Study period Study population Classification criteria Incidence per 100,000 population
GPA MPA EGPA
Adult cohort data
Watts et al. [12] UK 1988–1997 All ages CHCC/ACR 8.7–10.3 6.8–8.9 1.5–3.7
Watts et al. [13] UK 1990–2005 All ages Clinical diagnosis 8.4 - -
Koldingsnes et al. [14] Norway 1984–1998 Age >15 years ACR 6.0–14.4 - -
Gonzales-Gay et al. [15] Spain 1998–2001 Age >15 years CHCC 2.95 7.91 1.31
Reinhold-Keller et al. [16] Germany 1998–2002 All ages CHCC 6–12 2–3 0–2
Ormerod et al. [17] Australia 1995–2004 Age >15 years ACR/CHCC 8.4–8.8 2.3–5 2.2–2.3
Paediatric cohort data
Gardner-Medwin et al. [18] UK 1996–1999 Age <17 years ACR Primary systemic vasculitis incidence 10.6 per
100,000 patients (including
ANCA-vasculitis)
Grisaru et al. [19] Canada 1994–2009 Age <18 years ACR or EULAR/PRES 6.39 - -
GPA, Granulomatosis with polyangiitis; MPA, microscopic polyangiitis; EGPA, eosinophilic granulomatosis with polyangiitis; CHCC, Chapel Hill
Consensus conference; ACR, American College of Rheumatology; PRES, Paediatric Rheumatology European Society; EULAR European League
Against Rheumatism; ANCA, anti-neutrophil cytoplasmic antibody
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While numbers were limited, oliguria, markedly reduced
GFR, nephrotic-range proteinuria and chronic glomeru-
lar lesions were associated with poorer outcomes [35].
Arthralgia and myalgia are reported in up to 64% of pa-
tients at presentation and are deemed to be early markers for
disease flare. Arthritis is less common (20–32%) and seen in
the context of active disease [1]. Ocular involvement has been
reported in up to 53% of paediatric patients. Inflammatory
changes can occur in any compartment causing proptosis
[36], conjunctivitis, episcleritis and uveitis. Venous thrombo-
sis is an uncommon finding, having been reported in 12% of
paediatric patients [1]. Cutaneous involvement affects up to
53% of patients at presentation and includes palpable purpura,
which is often mistaken for immunoglobulin A (IgA) vascu-
litis (the new term for Henoch–Schönlein purpura), petechiae
and nodules. Nervous system involvement is uncommon al-
though symptoms can range from headache and dizziness to
acute mononeuritis. Cerebellar involvement, seizures and up-
per motor neurone signs have all been described in children
with GPA [1, 2].
Microscopic polyangiitis
Microscopic polyangiitis is a rare disease in childhood and is
characterized by a multi-system pauci-immune necrotizing
small-vessel vasculitis without granulomatous inflammation.
Prior to ARChiVe, evidence of paediatric presentation and
disease course in MPA was limited [14, 15]. Recently, how-
ever, the ARChiVe Investigators Network described the larg-
est paediatric MPA cohort to date (48 patients) using EMA
criteria [32].
As with GPA, a female predominance is seen in childhood
(as high as 6:1 [14]). Patients are significantly younger than
those with GPA (11 vs. 14 years) [32]. Onset is insidious and
associated with constitutional symptoms in almost all patients
[15, 32]. Purpuric rash at presentation is common although
other skin lesions include necrotizing vasculitis and lesions
mimicking pyoderma gangrenosum [14]. The incidence of
central nervous system involvement has varied between co-
horts, ranging from 21 to 86%. In the cohort study by the
ARChiVe Investigators Network symptoms included seizures,
optic neuritis and peripheral neuropathy. Pulmonary symp-
toms including cough, haemoptysis and dyspnea were present
in 44% of cases, although symptoms were less frequent and
severe than in GPA patients. Using EMA criteria, gastrointes-
tinal symptoms including chronic nausea and non-specific
abdominal pain were also seen in the majority of patients
(58%) [32].
Renal involvement is common at presentation (75–90%)
[14] and often follows a more severe course than that seen in
paediatric GPA [32, 35]. In the ARChiVe Investigators
Network study, three-quarters of patients described using
EMA criteria demonstrated renal involvement, with
manifestations including proteinuria, microscopic haematuria
and renal dysfunction with moderate to severely elevated se-
rum creatinine levels (>30% age-adjusted upper limit of nor-
mal) in 48% of affected patients. Hypertension was noted in
one-third of cases, while RRT was required in one-quarter of
patients at presentation. Delay in diagnosis and higher
Birmingham vasculitis activity scores (BVAS) have been as-
sociated with poor renal outcome [14].
Bakkaloglu et al. reported a high incidence of acute kidney
injury at presentation (6/10 patients), with one-half of the pa-
tients requiring RRT in association with pulmonary involve-
ment and high MPO-ANCA titres [150–250 endotoxin units
(EU)/ml]. All patients with pulmonary–renal involvement
progressed to end-stage kidney disease (ESKD) within 1 to
5 years. Hypertension was present in 83% (5 of 6) MPA pa-
tients with renal involvement, with evidence of renal artery
aneurysms in one patient [15].
Renal limited vasculitis
Renal limited vasculitis (RLV) is a term used for renal
histopathology [previously classified as pauci-immune,
necrotizing crescentic (NCGN) or ANCA-associated glo-
merulonephritis (AAGN)] in the absence of vasculitis in
other organs. Approximately 80% of patients with RLV
will be positive for ANCA, predominantly MPO-ANCA,
and as such may be cohorted with patients diagnosed as
MPA [37]. In children, AAGN is the second commonest
cause of rapidly progressive glomerulonephritis (RPGN)
behind immune-mediated pathologies, such as post-infec-
tious, IgA vasculitis and IgA nephropathy. In a single-
centre study of RPGN, pauci-immune crescentic GN was
observed in 31/73 patients aged between 1 and 20 years
[37]. In a retrospective study for the Japanese Society of
Paediatric Nephrology, Hattori et al. reported a mean age
at presentation of 11.9 years (Table 2) and female prepon-
derance (6.8:1). Of the ten patients described, seven were
detected through national screening, while three presented
with constitutional symptoms of malaise, anorexia, fever
and weight loss. During a median follow-up period of 3.9
(range 1.3–4.9) years, no patients developed evidence of
extra-renal disease [38].
Eosinophilic granulomatosis with polyangiitis
Eosinophilic granulomatosis with polyangiitis is extremely
uncommon in children and is thought to contribute 2% of all
paediatric PSV. It is a necrotizing vasculitis of small- and
medium-sized vessels that predominantly affects the upper
airways and lungs. Extra-pulmonary disease including cuta-
neous, cardiac, neurological and gastrointestinal involvement
is common. The presence of ANCA is less common in paedi-
atric EGPA than in adult patients, with 0–25% cases testing
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positive. To date, 47 cases have been published within the
paediatric literature; none of which had evidence of renal in-
volvement [39]. We therefore aim to focus further discussion
within this review on the management of GPA and MPA only.
Renal histology in AAV
Renal biopsy remains the ‘gold standard’ in diagnosing
AAGN. Classically, AAGN is characterized by a pauci-
immune crescentic necrotizing glomerulonephritis on light
microscopy. Histopathological features may vary, including
acute lesions such as glomerular crescents or tubular intra-
epithelial infiltrates to lesions indicative of chronic inflamma-
tion, i.e. glomerulosclerosis, interstitial fibrosis or tubular at-
rophy [26]. Electron microscopy features include
subendothelial oedema, microthrombi and degranulation of
neutrophils [31]. While a paucity of immune deposits is con-
sidered typical, there are a few cases of childhood AAV in
which immune deposition has been seen on examination by
electron microscopy [35]. It is speculated that their presence
may somehow potentiate the effect of ANCA in the develop-
ment of glomerulonephritis [25].
Glomerulonephritis in MPA patients tends to be asso-
ciated with a greater degree of chronic lesions, whereas
a greater proportion of normal glomeruli are seen in
GPA. In a paediatric study of MPA, findings included
focal segmental necrosis of glomeruli among those chil-
dren with a shorter duration between symptom onset
and diagnosis, while those with greater delay demon-
strated circumferential fibrous and/or fibro-cellular cres-
cents [15]. This finding is supported by other studies
[35, 38]. Glomerulosclerosis is also more prominent in
patients positive for MPO-ANCA, which suggests the
pathogenesis of renal disease may differ between
ANCA subtypes [26].
Adult studies have attempted to delineate the prog-
nostic value of pathologic lesions on biopsy alongside
patient demographics. Baseline GFR has been shown to
correlate with renal function at 18 months of follow-up
[40]. ANCA subtype was found not to be independently
linked to renal prognosis. The percentage of normal
glomeruli has been shown to strongly correlate with
renal function [30] at baseline and follow-up [28]. In
terms of acute lesions, the presence of cellular crescents
is associated with improvements in renal function inde-
pendent of baseline GFR, suggesting a potential revers-
ibility of active disease [40]. Conversely, fibrous cres-
cents correlate with RRT requirement at baseline and a
poor renal outcome [28]. Chronic lesions including glo-
merular sclerosis and tubular atrophy, as well as degree
of proteinuria at baseline relate to poor long-term out-
comes [30, 41].
Collating this information, an international working group
in 2010 proposed a new histopathologic classification for
AAGN that features four distinct categories: focal, crescentic,
mixed and sclerotic [42–44]. This classification system has
since been validated in children with AAGN over a median
follow-up period of 2.4 years, demonstrating a probability of
an estimated GFR (eGFR) of >60ml/min/1.73m2 at 2 years as
100% for focal lesions, 56.5% for crescentic/mixed and 0%
for sclerotic biopsy categories [45].
Measurement of disease activity
Formal measurement of disease activity is essential to
assess treatment efficacy in clinical practice and thera-
peutic trials. In adults, the BVAS and Vasculitis Activity
Index are disease tools that have been validated in AAV
[46, 47]. These tools have undergone a number of
changes, including disease-specific modifications for
GPA (formerly known as BVAS-WG).
Recently International collaborative working groups
have emphasized the need to develop a robust
paediatric-specific disease measurement tool. The devel-
opment of the Paediatric Vasculitis Activity Scale has
shown strong correlation with physician assessment,
erythrocyte sedimentation rate and treatment decision,
as well as high agreement between assessors [48].
Investigations
Primary systemic vasculitis should be considered in any
child presenting with a multi-system disease. Investigations
which should be performed in children when there is a sus-
picion of AAV are listed in Table 3. It is important to ex-
clude differential diagnoses such as infection or malignancy.
Immunological testing is important in the work-up of
ANCA-associated and PSV. ANCA positivity by enzyme-
linked immunosorbent assay or indirect immunofluores-
cence testing in the paediatric population has a sensitivity
93% and specificity of 90% [5]. GPA is frequently associ-
ated with elevated titres of ANCA directed at PR3 that lead
to cytoplasmic staining of neutrophils (cANCA), whilst
MPA is frequently associated with antibody directed against
MPO that stains neutrophils in a perinuclear fashion
(pANCA) [49].
Glomerulonephritis may present as haematuria and/or pro-
teinuria on dipstick testing, or in a more pronounced fashion,
with hypertension, oligo-anuria and/or nephrotic-range pro-
teinuria. Early renal biopsy should be considered in patients
with renal involvement.
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Management
Modern immunosuppression has increased the survival rates
of patients with AAV. Treatment is based on intensive remis-
sion induction followed by maintenance therapy.
At present, there are very little data to allow the develop-
ment of a paediatric-specific AAV guideline. The SHARE
project, a European initiative, aims to provide treatment rec-
ommendations for the care of children and young adults with
vasculitis. These recommendations are currently awaited and
Table 3 Suggested
investigations in suspected anti-
neutrophil cytoplasmic antibody-
associated vasculitis
First-line investigations Second-line investigations
Haematology
-Full blood count with blood film
-Erythrocyte sedimentation rate
-Coagulation profile
Biochemistry/Immunology
-Basic lymphocyte subsets
-CD19 count (pre-rituximab)
-Hepatitis B&C, parvovirus B19, human
immunodeficiency virus
-Mantoux and/or quantiferon tuberculosis testing
-Ebstein–Barr virus, cytomegalovirus,
enterovirus, adenovirus, JC virus
Biochemistry
-Urea & electrolytes
-Liver function tests
-Lactate dehydrogenase
-Creatinine kinase
-Thyroid function
-Pancreatic function (amylase/lipase)
-Urine albumin:creatinine ratio
Imaging
-Computed tomography/magnetic resonance im-
aging (MRI) /X-ray sinuses and/or thorax
-Renal dimercaptosuccinic acid scan
-MRI/MR angiography head
Infectious disease screen
-Blood culture
-Urine microscopy and cell culture
-Mycoplasma serology
-Anti-streptolysin titre
-Anti-DNase B
Neurological
-Nerve conduction studies
Immunological tests
-Anti-neutrophil cytoplasmic antibodies
-Antinuclear antibodies
-Anti-extractable nuclear antibodies
-Rheumatoid factor
-Anti-double stranded DNA antibodies
-Anti-glomerular basement membrane antibodies
-Coeliac screen
-Complement (C) function: C3/4, CH100, Mannose
binding lectin
-Anti-cardiolipin antibodies
-Lupus anticoagulant
-Varicella status
-Immunoglobulins (Ig): IgG, IgM, IgA, IgE
-Serum angiotensin converting enzyme
Other
-Histology: renal/lung biopsy
-Ambulatory blood pressure monitoring
-Formal glomerular filtration rate testing
Other
-Chest X-ray
-Electrocardiography
-Echocardiography
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will be based on surveys sent to PRINTO members of current
clinical practice and systematic literature reviews [50].
Therefore, this review will provide information based on the
authors’ experience and the evidence obtained from the limit-
ed number of randomized controlled trials (RCTs) performed
in adults extrapolated to children (Fig. 1). While GPA and
MPA are considered separate entities, the two are managed
identically with regards to therapeutic intervention.
A recent study from the ARChiVE group demonstrated
significant concordance between treatment intensity and the
European Vasculitis Study Group (EUVAS) subgroupings in
125 paediatric patients [51]. Therefore, we used these disease
categories to describe therapeutic options (Table 4).
Remission induction
The initial goal of therapy in AAV is to achieve remission,
formally defined using disease activity tools. Traditionally
severe disease including renal involvement has been man-
aged with the ‘gold standard’ treatment of glucocorticoids
and cyclophosphamide, with remission rates of between 70
and100% [43, 52–54]. Other agents employed in remission
induction include TNF-α therapy and mycophenolate mo-
fetil (MMF). Recently, however, increasing consideration
is being given to rituximab as an equally effective therapy
in severe or relapsing therapy, particularly for those pa-
tients at risk for glucocorticoid or cyclophosphamide
toxicity.
Patients with severe or generalized disease have historical-
ly received large amounts of immunosuppression given their
poor prognosis, including intravenous (IV) cyclophospha-
mide and methylprednisolone [52]. In such cases, adjuvant
therapy in the form of plasma exchange has been shown to
increase the renal survival in this cohort [53].
Cyclophosphamide
Cyclophosphamide is an alkylating agent that has long held a
key role in the remission induction and maintenance of PSV
and AAV. However, concerns do exist regarding cumulative
toxicity, particularly in children. High cumulative doses can
result in unacceptable adverse events, such as haemorrhagic
cystitis (43%), infertility (57% of females), opportunistic in-
fections (0.11 infections per patient-year) and a 2.4-fold in-
creased risk of malignancy, among others [54].
Research has focused on minimizing cumulative doses, as
well as determining equally effective alternatives. In AAV, a
meta-analysis has confirmed that IV cyclophosphamide pulse
therapy is as effective as cyclophosphamide administered as
daily doses and results in a smaller cumulative dose with few-
er adverse effects [55, 56].
Anti-TNF-α therapy
In AAV, it is thought that TNF-α is likely to play a role in
neutrophil priming, resulting in the expression of endothelial
adhesion molecules and ANCA antigens on the cell surface
[18]. The Wegener’s granulomatosis etanercept trial (WGET)
assessed the efficacy of etanercept, a TNF-α blocker, in re-
mission induction and remission maintenance of GPA [57,
58]. A total of 108 patients were randomized to receive either
etanercept or placebo in addition to standard therapy (cyclo-
phosphamide and corticosteroids for severe disease or metho-
trexate and corticosteroids for limited disease). No difference
in remission induction rates were seen between the two groups
Remission Inducon
Localised disease: 
Methotrexate and glucocorcoid therapy
Methotrexate (10-15mg/m2/dose) PO or SC weekly
PO prednisolone (30-60mg/m2/day or 1-2mg/kg) for a total of 
4 weeks before tapering over the following 6-8 weeks 
(depending on response to treatment). Aim to wean to 
0.5mg/kg/alternate day dosing. 
Generalised disease: 
Pulsed IV cyclophosphamide + methylprednisolone therapy
IV cyclophosphamide 0.5-1g/m2 monthly (with mesna to 
prevent cyss) for 6 months. Alternave is oral 
cyclophosphamide dosing (2-3mg/kg once daily for 2-3 
months).
IV methylprednisolone 30mg/kg (max 1g) once daily for three 
doses before conversion to oral prednisolone (as above).
Severe/ renal or life-threatening disease/refractory disease: 
Consider Rituximab, IV cyclophosphamide, plasma exchange (PEX), 
and/or IVIg alongside pulsed IV methylprednisolone.
Rituximab: 750mg/m2/dose IV (max 1000mg)- for two doses 
two weeks apart. 
Plasma exchange: 5 or 10-day course of 2-volume PEX with 
4.5% Human albumin soluon.
IVIg: 2g/kg.
Maintenance therapy
Localised/Early systemic disease: 
Methotrexate (as above) or Azathioprine (0.5-2.5mg/kg once 
daily PO for 1 year or more) with steroid tapering. 
Generalised: 
Azathioprine (as above)
Aim to wean steroids to maintenance dose of 
0.5mg/kg/alternate days, or oﬀ completely if stable.
Second line therapy
Localised/Early systemic: 
Consider leﬂunamide, MMF
Generalised: 
Consider rituximab, inﬂiximab, MMF, oral cyclophosphamide
Fig. 1 A treatment algorithm for anti-neutrophil cytoplasmic antibody-
associated vasculitis according to the severity of the presenting disease
and the treatment for both remission induction and maintenance of dis-
ease. POOral, SC subcutaneous, IV intravenous, IVIg intravenous immu-
noglobulin, MMF mycophenolate mofetil
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although an increase in solid cancers was noted in those pa-
tients receiving standard therapy combined with cyclophos-
phamide, suggesting a cumulative malignancy risk. Relapse
rates during maintenance therapy were similar.
Interestingly, whilst inhibition of TNF-α via etanercept has
shown no benefit in remission induction for either early system-
ic or generalized disease, anti-TNF-α antibodies, such as
infliximab and adalimumab, do show promise. In an open-
label prospective trial of 16 AAVadults with renal involvement,
adjuvant infliximab therapy was noted to achieve a mean time-
to-remission of 6.4 weeks when used alongside cyclophospha-
mide and enabled a significant reduction of steroid doses [59].
However, there have been no RCTs to confirm this finding to
date. The results of a prospective open-label study of adjuvant
adalimumab suggest that while remission rates are similar to
those seen with standard therapy alone (78.5% by week 14), a
significant steroid-sparing effect is present [60].
Mycophenolate mofetil
At present, there is limited evidence to support the use of
MMF in induction regimens for AAV. Recently, the results
of a non-inferiority trial were reported (‘MYCYC’; a random-
ized control trial of MMF vs. cyclophosphamide in remission
induction in AAV) [61]. The study comprised 140 newly di-
agnosed patients (70 per arm), including paediatric patients.
The primary outcome was remission, defined as absence of
disease activity for longer than 4 weeks when adhering to the
glucocorticoid regimen. The study was unable to demonstrate
that MMF is non-inferior to cyclophosphamide when adher-
ence is taken into account; however, the authors conclude that
further evaluation of how glucocorticoid treatment affects re-
mission induction is warranted [61].
Plasma exchange
Removal of circulating ANCA through plasma exchange is a
short-term measure often reserved for severe or refractory dis-
ease. It should be used in conjunction with immunosuppres-
sion. The MEPEX trial consisted of 137 patients with severe
renal vasculitis who were randomized to receive plasma
exchange versus pulsed methylprednisolone [44]. The results
demonstrated a 50% relative reduction in the need for RRT at
12 months in those who received plasma exchange, with no
difference in the frequency of adverse effects. The authors of a
meta-analysis of nine studies concluded that while renal sur-
vival with plasma exchange is encouraging (overall relative
risk of renal disease following adjuvant therapy 0.64, 95%
confidence interval 0.47–0.88, p = 0.006), there is insufficient
evidence to suggest whether it improves overall survival [53,
62], highlighting the need for larger studies. At the present
time there is little evidence of the effect of plasma exchange
on extra-renal manifestations [63]. An international open label
study is currently recruiting to address these questions [64].
With the aim of recruiting 700 patients, ‘PEXIVAS’ is a ran-
domized trial with the intent to compare adjuvant plasma ex-
change and two oral glucocorticoid regimens in patients un-
dergoing remission induction treatment, including adolescents
(aged >15 years). The primary outcome measure is mortality
from any cause and ESKD [64].
Maintenance therapy
Studies have confirmed findings that cyclophosphamide can
safely be substituted for maintenance azathioprine, thereby
avoiding large cumulative doses and their associated toxicity
[43]. Other options for remission maintenance in milder dis-
ease without renal involvement include methotrexate and
leflunamide. MMF may be considered for patients in whom
azathioprine is poorly tolerated, although it appears less effi-
cacious [65].
Azathioprine
In terms of the maintenance of disease control, the
CYCAZAREM trial (randomized trial of Cyclophosphamide
versus Azathioprine during Remission in ANCA-positive sys-
temic vasculitis) demonstrated no significant differences in
rates of relapse between patient groups at 18 months [15.5 vs.
13.7% in cyclophosphamide and azathioprine (AZA) groups,
respectively] [43]. Subsequent retrospective studies with longer
follow-up periods demonstrated a slightly higher relapse rate in
Table 4 European Vasculitis
Study Group definitions used in
cases of anti-neutrophil cytoplas-
mic antibody-associated vasculi-
tis based on the severity and ex-
tent of disease
Category Description
Localized Upper and/or lower respiratory symptoms without other system involvement or constitutional
symptoms
Early systemic Disease without threatened organ function or life-threatening disease (also known as
‘non-organ or life threatening’
Generalized Renal, or other organ-threatening disease. Serum creatinine <500 μmol/l (or 5.6 mg/dl)
Severe Renal or other organ failure, serum creatinine >500 μmol/l (5.6 mg/dl). Also known as
‘immediately life threatening’
Refractory Disease unresponsive to glucocorticoids and cyclophosphamide
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patients treated with azathioprine (42.3 vs. 57.4%) at 5 years
[66]. Many of the relapses reported however occurred follow-
ing discontinuation of therapy and were more frequent in pa-
tients positive for PR3-ANCAwhen starting therapy.
Mycophenolate mofetil
The IMPROVE study (InternationalMMF Protocol to Reduce
Outbreaks of Vasculitides), an open-label, multi-center RCT,
was designed to assess whether MMF reduced the risk of
relapse compared with azathioprine for AAV patients in re-
mission [65]. The results demonstrated an inferior effect to
that of AZA in sustaining disease-free survival (55.3 vs.
37.5%). No differences in the number of adverse effects were
reported, but in view of these results, AZA is generally pre-
ferred over MMF for remission maintenance. As an alterna-
tive, and in those with milder disease (including adequate
renal function), methotrexate may be safely used for mainte-
nance of remission in this cohort [63]. Leflunamide is reported
to be more efficacious than methotrexate, but it is associated
with greater adverse effects [67].
Management of refractory disease
Similar to severe disease, progressive, unresponsive disease in
AAVis associated with significant mortality that is both disease-
and therapy-related. In these circumstances, further courses of
induction treatments should be considered, such as IV cyclo-
phosphamide, methylprednisolone, infliximab, and plasma ex-
change. Biologic agents play a significant role in these patients.
Rituximab
There is increasing evidence that rituximab has a short- and
medium-term benefit in both severe and refractory disease. For
children who are at particular risk of toxicity from both cyclo-
phosphamide and corticosteroids, rituximab is likely to provide
an alternative, equally efficacious means by which disease ac-
tivity can be managed. In AAV, chronic T-cell activation is
thought to promote maturation of auto-reactive B cells, which
in turn leads to the production of ANCA. Rituximab, a chime-
ric monoclonal anti-CD20 antibody, causes B cell depletion
and has been evaluated in two RCTs for remission induc-
tion—RAVE and RITUXVAS [68, 69]. A further evaluation
of its use in remission maintenance, the MAINRITSAN study,
has also been published with positive results [70].
The RAVE trial (Rituximab in ANCA-associated
Vasculitis) was a multi-center RCT designed to assess the
use of rituximab versus cyclophosphamide in remission in-
duction [69]. New patients or those with relapsing disease
were randomized to receive either rituximab (375 mg/m2 IV
weekly for 4 weeks) or oral cyclophosphamide (2mg/kg/day).
Patients with severe renal disease were excluded. Patients in
the cyclophosphamide arm who achieved remission between
3 and 6 months were eligible to switch to AZA for the remain-
der of the study whilst the rituximab group received placebo.
A total of 197 AAV patients were recruited. Rituximab was
found to be non-inferior when compared with cyclophospha-
mide for achieving disease remission by 6 months. In patients
with relapsing disease, rituximab was superior. No difference
was seen with regards to adverse effects or steroid exposure.
The RITUXVAS trial compared rituximab (375 mg/m2 IV
weekly for 4 weeks administered with 2 × 15 mg/kg IV cyclo-
phosphamide) to the ‘gold standard’ IV cyclophosphamide reg-
imen (6–10 doses at 15 mg/kg) for new AAV patients and
included those with renal involvement [68]. The results demon-
strated that rituximab is as effective as cyclophosphamide in
inducing remission, with both achieving high remission rates
(76% in rituximab arm vs. 82% in cyclophosphamide arm).
Similar numbers of adverse effects were reported (18% mortal-
ity in both treatment arms). Further data from the RITUXVAS
group at 2 years of follow-up has revealed no differences be-
tween rituximab and control with regards to a composite out-
come of death, ESKD or relapse. While no relapses were dem-
onstrated in B-cell-depleted patients, B-cell return alone was not
felt to be a sufficient marker for potential relapse: only 30% of
patients with B-cell return had a confirmed clinical relapse. No
differences in patients achieving ANCA negativity were noted
(88% in rituximab vs. 73% in cyclophosphamide group) [71].
Subsequent prospective data from the RAVE group demon-
strates that there is no difference in remission rates when ritux-
imab was given to patients from both treatment arms for re-
lapse. This result suggests that the effect of rituximab is not
dependent on the initial remission-induction agent used. Again,
ANCA and B-cell counts were not predictive of relapse [72].
With respect to remission maintenance, rituximab has been
compared in a non-blinded RCT with AZA in the
MAINRTISAN study (Maintenance of Remission using
Rituximab in Systemic ANCA-associated vasculitis) [70].
Eligible patients included those with biopsy-proven ANCA-
positive GPA,MPA or renal-limited AAV. Following the induc-
tion of remission, patients were randomized to receive either
fixed doses of rituximab 500mg at days 0 and 14 andmonths 6,
12 and 18 after first infusion, or control AZA at 2 mg/kg daily
for 12 months, followed by 1.5 mg/kg daily for a further
6 months. The primary outcome was percentage of patients
who experienced a major relapse (BVAS score >0 and involve-
ment of one major organ) at month 28. A total of 115 patients
underwent randomization, with each group having similar base-
line characteristics and proportions of relapsing disease. There
were fewer major relapses in the rituximab group than in the
control group (hazard ratio for relapse 6.61, 95% confidence
interval 1.56–27.96, p = 0.002), with similar severe adverse ef-
fects noted in both groups.
An international open-label RCT comparing rituximab and
AZA as maintenance therapy in relapsing AAV is currently
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recruiting (the ‘RITZAREM’ study). Remission induction will
be achieved with rituximab (4 × 375 mg/m2) followed by
randomization to fixed-interval repeat dosing or AZA for
24 months. It is anticipated that 160 patients will be recruited
for a follow-up study period of 4 years. Retrospective evi-
dence suggests fixed-interval dosing confers a greater clinical
benefit to patients without additional adverse effects, although
randomized studies are required to confirm this finding [73].
In refractory disease, adjuvant therapy with infliximab or
rituximab alongside conventional immunosuppression has
been compared in a prospective RCT. Although the trial in-
volved only a small number of patients, results suggested ri-
tuximab was more effective at obtaining and sustaining remis-
sion over a mean follow-up of 31 months [74].
Rituximab use has been described in 13 paediatric patients.
In one study, the administration of rituximab resulted in sig-
nificantly improved BVAS scores and enabled steroid
weaning in four children with GPA [75]. Other case series
report high remission rates for both GPA andMPA even when
conventional treatments have failed. A phase IIa international
multi-center open-label trial is currently ongoing to evaluate
the safety and pharmacokinetics of rituximab in children with
severe AAV (The ‘PEPRS’ study; NCT01750697). Newly
diagnosed patients or those with relapsing disease who have
not previously received rituximab will be eligible for inclu-
sion. Recruitment commenced in 2013 and follow-up will
continue for approximately 3.5 years.
Current expert consensus recommends the use of rituximab
for remission induction in refractory disease, or where there
are concerns regarding cumulative cyclophosphamide or cor-
ticosteroid toxicity, particularly in children [76, 77].
Recommendations also include repeat treatment where relapse
occurs following a rituximab-induced remission.
IV Immunoglobulin
Intravenous immunoglobulin (total dose 2 g/kg) as adjuvant
therapy was effective at producing a significant short-term
improvement in disease activity compared with placebo in a
RCT [78]. However, the effect was short lived, and no differ-
ences between groups were noted at 3 months.
Future therapies
Given the success of rituximab, further work is ongoing to
identify alternative therapies for B-cell depletion. A novel
fully humanized monoclonal anti-CD20 antibody,
ocrelizumab, has been trialed in rheumatoid arthritis [79].
Initial safety data suggest that ocrelizumab is well tolerated,
rapidly depletes B cells with clinical improvement and has
similar adverse effects when compared with standard
treatment.
Renal transplantation in AAV
Despite improved recognition and management of the AAV,
progression to ESKD still occurs in a significant proportion of
patients. While the paediatric literature is limited, both renal
and non-renal relapses have been reported in adult patients
with GPA, MPA and RLV. In a pooled analysis of published
data, the recurrence rate for adults post-renal transplantation
was reported to be 17.3% (127 patients), with no differences
in relapse rate noted between the three disease entities.
Average time from transplant to relapse was 31 months.
Duration of time on dialysis, ANCA subtype, ANCA positiv-
ity at time of transplantation, allograft type (deceased or live)
and immunosuppression regimen (with or without
ciclosporin) had no clear effect on relapse rate [80].
More recently, a large retrospective study of 85 patients
reported a low relapse rate of 0.02 per patient-year (median
follow-up 64months, range 3–165months) on a prednisolone,
MMF and tacrolimus regimen post-transplantation, with low-
er relapse rates than in patients on dialysis, perhaps the result
of immunosuppression regimens used post-transplantation
[81]. Renal function post-transplantation is also comparable
to control subjects, with similar patient and graft survival rates
seen at 1, 5 and 10 years of follow-up [81, 82]. Therefore,
despite the perpetual risk of relapse, kidney transplantation
is recommended for patients with ESKD during clinical re-
mission, regardless of ANCA status [80, 81].
Prognosis
Most of our knowledge regarding the long-term outcomes of
AAVis based on adult data. In children, the majority of studies
have a limited follow-up: to date, seven case series describe a
total of 86 paediatric patients with AAV, with follow-up pe-
riods ranging from 4 months to 11 years. Compared with adult
data, long-term disease or treatment-related morbidity is re-
portedly lower (22 vs. 45% [33]), however the data are weak
and the burden is still significant. A recent study of children
followed up into adulthood (median of 18.5 years, range 11–
30 years [3]) described eight patients with relapsing disease.
One death was noted secondary to respiratory complications
of GPA. With regards to treatment-related morbidity, 50% of
patients were infertile, 7 patients suffered infections, one pa-
tient developed a malignancy and two developed skeletal
complications secondary to corticosteroid treatment. One-
half of all patients developed ears, nose, and throat complica-
tions, including hearing loss (4 patients), nasal septum (2 pa-
tients) or upper airway deformities (1 patient). All but one
patient had received cyclophosphamide, with five patients re-
quiring repeated courses. Biological agents were used in three
patients, with higher rates of infection seen with infliximab.
The s t udy empha s i z e s t h e ne ed f o r e f f e c t i v e
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immunosuppressive regimens while minimizing adverse ef-
fects: paediatric patients are at potentially greater risk of
long-term morbidity due to their age and cumulative exposure
and are therefore likely to benefit most from further research
in this field.
Conclusion
Anti-neutrophil cytoplasmic antibody-associated vasculitis is
a rare condition in children, but one that is associated with
significant morbidity and mortality. The exact pathogenesis
remains unknown, and it is likely to be multifactorial.
Understanding some of the immune mechanisms underlying
the disease has led to the addition of biologic therapies as
feasible management options. The evidence base for manage-
ment, especially in children, is limited; however, early aggres-
sive immunosuppression is strongly recommended to achieve
a prompt disease remission, and subsequent careful monitor-
ing is required to assess for disease relapse. European initia-
tives may provide standardized guidance on management in
the near future. Renal involvement is often associated with a
worse long-term outcome, although renal transplantation re-
mains an option in those who progress to ESKD.
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